Millennium Management LLC Acquires 103,013 Shares of ASLAN Pharmaceuticals Limited (NASDAQ:ASLN)

Millennium Management LLC increased its holdings in shares of ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) by 8.3% in the second quarter, according to its most recent filing with the SEC. The fund owned 1,349,288 shares of the company’s stock after acquiring an additional 103,013 shares during the period. Millennium Management LLC owned about 3.55% of ASLAN Pharmaceuticals worth $4,453,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. JPMorgan Chase & Co. purchased a new position in ASLAN Pharmaceuticals during the 1st quarter worth $47,000. Geode Capital Management LLC purchased a new position in ASLAN Pharmaceuticals during the 1st quarter worth $70,000. Jump Financial LLC purchased a new position in ASLAN Pharmaceuticals during the 2nd quarter worth $123,000. Schonfeld Strategic Advisors LLC purchased a new position in ASLAN Pharmaceuticals during the 1st quarter worth $168,000. Finally, Virtu Financial LLC increased its holdings in ASLAN Pharmaceuticals by 346.2% during the 1st quarter. Virtu Financial LLC now owns 61,997 shares of the company’s stock worth $208,000 after purchasing an additional 48,102 shares during the period. 73.37% of the stock is owned by hedge funds and other institutional investors.

Shares of NASDAQ:ASLN opened at $1.49 on Thursday. ASLAN Pharmaceuticals Limited has a 12-month low of $1.38 and a 12-month high of $6.75. The business’s fifty day simple moving average is $1.87 and its 200-day simple moving average is $2.59. The company has a market capitalization of $56.61 million, a PE ratio of -3.10 and a beta of 2.40. The company has a current ratio of 16.60, a quick ratio of 18.31 and a debt-to-equity ratio of 0.45.

ASLAN Pharmaceuticals (NASDAQ:ASLN) last announced its quarterly earnings results on Monday, October 25th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.13) by $0.01. Research analysts predict that ASLAN Pharmaceuticals Limited will post -0.47 EPS for the current year.

Several research analysts have commented on the company. Zacks Investment Research downgraded ASLAN Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, November 1st. BTIG Research restated a “hold” rating on shares of ASLAN Pharmaceuticals in a report on Tuesday, October 5th. Finally, HC Wainwright reiterated a “buy” rating and issued a $8.00 price target on shares of ASLAN Pharmaceuticals in a report on Tuesday, September 28th.

ASLAN Pharmaceuticals Company Profile

Aslan Pharmaceuticals Ltd. is a clinical-stage oncology-focused biopharmaceutical company, which engages in the development of novel therapeutics. It focuses on atopic dermatitis, other immunology indications and autoimmune disease. Its pipeline includes varlitinib, ASLAN003, ASLAN004, and AhR Antagonist.

Recommended Story: How to Use the MarketBeat Retirement Calculator

Institutional Ownership by Quarter for ASLAN Pharmaceuticals (NASDAQ:ASLN)

Receive News & Ratings for ASLAN Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASLAN Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.